Chronic recurrent multifocal osteomyelitis

Last updated on: 09.12.2023

Dieser Artikel auf Deutsch

History
This section has been translated automatically.

Giedion et al (1972) were the first to describe a syndrome known as chronic recurrent multifocal osteomyelitis (CRMO).

Definition
This section has been translated automatically.

Chronic recurrent multifocal osteomyelitis-3 (CRMO) is an autosomal dominant autoinflammatory bone disease characterized by early childhood bone pain and arthritis due to sterile osteomyelitis. The disease results from constitutive activation of the IL1-mediated inflammatory pathway due to loss of sensitivity of the IL1 receptor to its antagonist IL-1RN. Wang et al. (2023) proposed the term "Loss of IL1R1 Sensitivity to IL1RA (IL1RN)" or "LIRSA" to describe this disease.

Etiopathogenesis
This section has been translated automatically.

Although the exact molecular pathophysiology of CRMO is not yet fully understood, it seems likely that variable defects in the TLR4/MAPK/inflammasome signaling cascade lead to an imbalance between pro- and anti-inflammatory cytokine expression in monocytes of CRMO patients. This imbalance leads to sterile autoinflammation of bone and other organs (especially skin).

Clinical features
This section has been translated automatically.

The inflammation exhibits both subacute and chronic features. The lesions predominantly affect the metaphyses of the long bones, including the spine (Chun CS 2004). However, localized osteomyelitis (jaws) has also been described, also in connection with pustulosis palmo-plantaris (Brand CU et al. (1996). No pathogens are isolated from the affected areas!

Associations are given with:

Case report(s)
This section has been translated automatically.

Wang et al. (2023) reported on a 13-year-old girl with CRMO3 who had a mutation in the IL1R1 gene. She presented at the age of 15 months with left knee swelling and arthralgia. During childhood, she developed arthritis in her shoulders, elbows, wrists, hips, knees and ankles. She suffered from chronic pain, gait disturbances and poor overall growth. A skin rash and recurrent fever were not observed.

Radiographs showed heterotopic ossification, osteolytic lesions and multifocal metaphyseal lesions. Laboratory tests revealed an increase in serum amyloid A, C-reactive protein (CRP; 123260) and erythrocyte sedimentation rate (ESR), indicating an inflammatory process. Serum concentrations of inflammatory cytokines, including IL-1B, IL-6 and IL-8, were elevated. Antinuclear antibodies (ANA) were positive (1:100), IgA was elevated. Therapy: Treatment with TNF inhibitors generally did not lead to significant clinical improvement and treatment with a monoclonal antibody against IL1B (canakinumab) generally led to a rapid and significant clinical improvement and a reduction in inflammatory marker values (case report from: Wang Y et al. 2023).

A 12-year-old girl presented with recurrent erythematous palmoplantar plaques and pustules. She also complained of left ankle pain that had started 7 months earlier. Previous magnetic resonance imaging (MRI) scans had consistently shown multifocal bone edema of the left foot. Symptoms such as weakness, fever and morning stiffness were not present. The family history was unremarkable. Active range of motion of the left upper ankle was painfully limited by 50%. Laboratory results showed a slight increase in inflammatory parameters, including c-reactive protein and erythrocyte sedimentation rate. The tests for antinuclear antibodies, rheumatoid factor, HLA-B27 and Lyme disease were negative (case report from: Epple A et al. 2018).

Literature
This section has been translated automatically.

  1. Brand CU et al. (1996) Pustulosis palmoplantaris associated with chronic recurrent multifocal osteomyelitis of the mandible. Br J Dermatol 134:977-979.
  2. Byrd, L., Grossmann, M., Potter, M., Shen-Ong, G. L. C. Chronic multifocal osteomyelitis, a new recessive mutation on chromosome 18 of the mouse. Genomics 11: 794-798, 1991 [PubMed: 1686018, related citations] [Full Text]
  3. Chun CS (2004) Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature. Pediatrics 113:e380-4.
  4. Cox AJ et al. (2017) Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO). PLoS One 12: e0169687
  5. Epple A et al. (2018) Chronic recurrent multifocal osteomyelitis with psoriatic skin manifestations in a 12-year-old female. Dermatol Pract Concept 8:297-298.
  6. Ferguson PJ et al. (2006) A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone 38: 41-47.
  7. Figueras-Nart I et al. (2019) Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases. Front Immunol. 10:2448.
  8. Giedion A et al. (1972) Subacute and chronic 'symmetrical' osteomyelitis. Ann Radiol 15: 329-342.
  9. Golla A et al. (2002) Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22. Europ J Hum Genet 10: 217-221
  10. Greenwood S et al (2017) SAPHO and Recurrent Multifocal Osteomyelitis. Radiol Clin North Am 55:1035-1053.
  11. Prose NS et al (1994) Pustular psoriasis with chronic recurrent multifocal osteomyelitis and spontaneous fractures. J Am Acad Dermatol 31:376-379.
  12. Schaen L et al. (1998) Skin ulcers associated with a tender and swollen arm. Pyoderma gangrenosum (PG) in association with chronic recurrent multifocal osteomyelitis (CRMO). Arch Dermatol 134:1146-1147
  13. Wang Y et al. (2023) Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design. Immunity 56: 1485-1501.e7
  14. Zhao DY et al. (2021) Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO). J Transl Autoimmun 4:100095.

Incoming links (1)

IL1R1 gene;

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Last updated on: 09.12.2023